Myeloma Therapy:: Pursuing the Plasma Cell Book

Preface vii

Contributors xiii

Section 1 Biolgoic Consideration and Myeloma

1 Staging in Multiple Myeloma Leonard T. Heffner 3

2 Epidemiology of Multiple Myeloma Amelia A. Langston Dixil Francis 9

3 Basic Biology of Plasma Cell Dyscrasias: Focus on the Role of the Tumor Microenvironment Marc S. Raab Kenneth C. Anderson 23

4 Biology-Based Classification and Staging of Multiple Myeloma Wee Joo Chng Peter Leif Bergsagel 41

5 Cytogenetic Abnormalities in Multiple Myeloma: The Importance of FISH and Cytogenetics Esteban Braggio Michael Sebag Rafael Fonseca 57

Section 2 Historical and Cytotoxic Agent-Based Therapies for Myeloma

6 Role of Autologous Stem Cell Transplantation in Multiple Myeloma Jean-Luc Harousseau 79

7 Maintenance Therapy in Multiple Myeloma Jonathan L. Kaufman Ronald Mihelic Sagar Lonial 91

8 Therapy for Patients not Eligible for Autologous Transplant Bringhen Sara Palumbo Antonio 99

9 Current Role of Anthracyclines in the Treatment of Multiple Myeloma Sikander Ailawadhi Asher Chanan-Khan 113

Section 3 Immune-Based Therapies

10 Allogeneic Transplantation for Multiple Myeloma FengrongWang Edmund K. Waller 125

11 Immunobiology and Immunotherapy of Multiple Myeloma Madhav V. Dhodapkar 143

12 Antibody and Other Immune-Based Therapies for Myeloma Nikhil C. Munshi Yu-Tzu Tai 167

Section 4 Existing Novel Agents

13 Thalidomide in Patients with Relapsed Multiple Myeloma Ashraf Badros 229

14 Thalidomide: Induction Therapy Francis K. Buadi S. Vincent Rajkumar 229

15 The Role of Bortezomib in the Treatment of Relapsed and Refractory Multiple Myeloma Paul G. Richardson Constantine S. Mitsiades Robert Schlossman Teru Hideshima Irene GhobrialNikhil C. Munshi Kenneth C. Anderson 239

16 Bortezomib as Induction Therapy in Patients with Multiple Myeloma M.V. Mateos J.F. San Miguel 253

17 Lenalidomide in Relapsed or Refractory Multiple Myeloma Sheeba K. Thomas Tiffany A. Richards Donna M. Weber 265

18 Lenalidomide for Initial Therapy of Newly Diagnosed Multiple Myeloma Shaji Kumar 279

Section 5 Current and Future Targets

19 The Role of Heat Shock Protein 90 as a Therapeutic Target for Multiple Myeloma Constantine S. Mitsiades Teru Hideshima Nikhil C. Munshi Paul G. Richardson Kenneth C. Anderson 291

20 The PI3 Kinase/Akt Pathway as a Therapeutic Target in Multiple Myeloma R. Donald Harvey Jeannine Silberman Sagar Lonial 309

21 The Mammalian Target of Rapamycin and Multiple Myeloma Patrick Frost Alan Lichtenstein 323

22 CDK Inhibitors in Multiple Myeloma Yun Dai Steven Grant 331

23 Fibroblast Gowth Factor Receptor 3 and Multiple Myeloma Victor Hugo Jimenez-Zepeda A. Keith Stewart 365

24 Histone Deacetylase Inhibitors in Multiple Myeloma Teru Hideshima 379

25 Death Receptors in Multiple Myeloma and Therapeutic Opportunities Faustino Mollinedo 393

26 Proteasome Inhibitors as Therapy in Multiple Myeloma Dharminder Chauhan Ajita Singh Kenneth Anderson 421

Section 6 Supportive Care

27 Pathophysiology of Bone Disease in Multiple Myeloma Tomer M Mark Roger N. Pearse 435

28 Anemia and Erythropoeitic Growth Factors in Multiple Myeloma Mark J Sloan Noopur Raje 455

29 Percutaneous Vertebroplasty and Balloon Kyphoplasty for the Treatment of Acute Painful Pathologic and Nonpathologic Fractures Sandra Narayanan Frank C. Tong 469

30 The Role of Anatomic and Functional Imaging in Myeloma Brian G.M. Durie 491

31 Management of Multiple Myeloma Patients with Renal Dysfunction Sikander Ailawadhi Asher Chanan-Khan 499

Section 7 Other Plasma Cell Disorders

32 Waldenstrom's Macroglobulinemia Lijo Simpson Morie Gertz 519

33 AL (Immunoglobulin Light-Chain) Amyloidosis Vaishali Sanchorawala 551

34 POEMS Syndrome and Other Atypical Plasma Cell Disorders Angela Dispenzieri 571

35 Monoclonal Gammopathy of Undetermined Significance Robert A. Kyle S. Vincent Rajkumar 625

Index 651